Recent Press Releases

Study Finds That Microinjection Platform Enables Assessment of Multiple Cancer Drugs Directly in Tumors, Predicts Systemic Response

– Data published in Science Translational Medicine show positive findings using patented new technology with multiple cancer drugs tested in xenografted mouse models and canine patients –...

3M Offers Clear Choice with New Tegaderm CHG I.V. Port Dressing

ORLANDO, Fla.--()--3M Critical and Chronic Care Solutions today announces the launch of its new 3M™ Tegaderm™ CHG Chlorhexidine Gluconate I.V. Port Dressing, designed for...

Generex Announces New $11 Million Collaboration on Buccal Cannabis

Generex to receive $10M in common stock, a warrant, & $1M in R&D funding WORCESTER, Mass. and TORONTO, April 23, 2015 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com)...

Provectus Biopharmaceuticals Opens Patient Enrollment; Begins Phase 3 International FDA Comparative Clinical Trial of PV-10 for Melanoma

Interim Data Expected When 50% of Events Achieved KNOXVILLE, Tenn.--(BUSINESS WIRE)-- Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT, http://www.pvct.com), a clinical-stage oncology and...

Icon Bioscience Announces Pivotal Phase 3 Clinical Data Demonstrates Exceptional Efficacy of IBI-10090 in Reducing Inflammation Associated with Cataract Surgery

SUNNYVALE, Calif., Apr 20, 2015 (BUSINESS WIRE) -- Icon Bioscience Inc., a specialty biopharmaceutical company focused on utilizing its patented and proprietary Verisome® extended-release drug...

Study Published in The Journal of Clinical Psychiatry Shows INVEGA SUSTENNA® Effective Six Months Longer Than Common Oral Antipsychotics in Treatment of Schizophrenia

Trial is the first to study schizophrenia treatment within the context of many real-world issues faced by patients with schizophrenia TITUSVILLE, N.J., April 15, 2015 /PRNewswire/ -- A study...

Study Published in The Journal of Clinical Psychiatry Shows INVEGA SUSTENNA® Effective Six Months Longer Than Common Oral Antipsychotics in Treatment of Schizophrenia

Trial is the first to study schizophrenia treatment within the context of many real-world issues faced by patients with schizophrenia. TITUSVILLE, N.J., April 15, 2015 /PRNewswire/ -- A study...

AngioDynamics Re-Entering Embolization Market

Company Announces Worldwide Licensing Agreement With EmboMedics Inc. ALBANY, N.Y., Apr 09, 2015 (GLOBE NEWSWIRE via COMTEX) -- AngioDynamics ANGO, +1.27% a leading provider of innovative,...

Edge Therapeutics Raises $72.5 Million Through Successive Series C-1 and C-2 Financings

Proceeds to Advance Development of EG-1962 and Earlier Stage Pipeline BERKELEY HEIGHTS, N.J., April 9, 2015 – Edge Therapeutics, a clinical-stage biotechnology company that discovers, develops...

Augmenix Announces Clearance of SpaceOAR® System

WALTHAM, Mass.—April 2, 2015—Augmenix, Inc., a privately held company developing minimally invasive hydrogel products to improve outcomes following cancer radiotherapy, today announced...

Alere Receives FDA Clearance for Alere™ i Strep A Rapid Molecular Test

Newest testing application on innovative Alere i molecular diagnostic platform detects Group A Streptococcus infections in 8 minutes or less WALTHAM, Mass., April 2, 2015 – Alere Inc. (NYSE:...

Particle Sciences Receives Patent for its Surface Arrayed Therapeutics Drug Delivery Platform

BETHLEHEM, Pa., April 6, 2015 /PRNewswire/ -- Particle Sciences, a leading drug delivery CDMO, has received a Notice of Allowance for composition and use of the technology incorporated into its...

Depomed Announces Closing of Acquisition of U.S. Rights to NUCYNTA® (tapentadol), NUCYNTA® ER (tapentadol) extended release tablets and NUCYNTA® (tapentadol) oral solution from Janssen Pharmaceuticals, Inc. for $1.05 billion

NEWARK, Calif., April 2, 2015 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) today announced that it has closed the acquisition of the U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals,...

TPG Completes Acquisition of Aptalis Pharmaceutical Technologies, Company Renamed Adare Pharmaceuticals

· Adare Pharmaceuticals provides enhanced medicines, creating new possibilities for improved patient health · Building upon its legacy, Adare Pharmaceuticals will expand...

BRILINTA Receives US FDA Approval for New Administration Option

BRILINTA® (ticagrelor) now the only P2Y12 inhibitor with an FDA approved crushing option for administration March 30, 2015 09:00 AM Eastern Daylight Time WILMINGTON, Del.--(...

Kala Pharmaceuticals Announces Positive Results from Phase 3 Trial of KPI-121 in Cataract Surgery

KPI-121 meets all primary endpoints, achieving statistical superiority over vehicle for elimination of inflammation and pain following cataract surgery when dosed either twice or four times daily...

Columbia Laboratories Acquires Exclusive Worldwide License to a Novel Segmented Intra-vaginal Ring Delivery Technology

BOSTON, March 30, 2015 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company"), a specialty pharmaceutical company focused on the development of...

Genisphere's 3DNA® Drug Delivery Platform Achieves Success in Preclinical Treatment of Posterior Capsular Opacification (PCO)

HATFIELD, Pa., March 26, 2015 /PRNewswire/ -- Genisphere LLC, provider of the 3DNA® nanotechnology platform, reported today it has achieved specific immunodepletion of problematic Myo/Nog cells...

Neurotech Announces FDA Acceptance of Investigational New Drug Application and Clinical Trial Initiation of Novel Therapy for Wet AMD

Efficacy and Safety of Long-term, Continuous Anti-VEGF will be Assessed in Phase 2 Study CUMBERLAND, R.I., March 30, 2015 /PRNewswire/ -- Neurotech Pharmaceuticals, Inc. announced today that the U.S....

Novan Secures $50 Million Private Financing

Funds Intended to Advance SB204 into Phase 3; Company Expands Board with the Addition of Three Directors DURHAM, N.C. (March 15, 2015) - Novan Therapeutics, a clinical-stage biotechnology company...